Revive Therapeutics Ltd C.RVV

Alternate Symbol(s): RVVTF

Healthcare

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).

CSE:RVV - Post by User

Revive Therapeutics Ltd

<< Previous

Bullboard Posts

Next >>

Post by cool888on Mar 05, 2023 9:24am

198 Views

Post# 35319833

The FDA has rejected a Veru drug in severe COVID.

#Bucillamine

UPDATED: Friday, March 3 at 10:50 a.m. ET

The FDA has denied Veru's sabizabulin an emergency use authorization in hospitalized patients with moderate to severe COVID who are at high risk for acute respiratory distress syndrome. Despite the rejection, the FDA provided guidance on the design of a proposed phase 3 trial of the drug. Veru said it expects to communicate more details on the phase 3 study soon. In a previous phase 3, sabizabulin led to a 24.9% absolute reduction in deaths compared with placebo in hospitalized patients. But the result came from just 150 patients.

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth